AnGes MG Inc. And Seikagaku To Dissolve Joint Development Agreement For NFkB Decoy-Oligo-Based Intraarticular Injection

February 6, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Tokyo, Feb 6, 2006 (JCN) - AnGes MG and Seikagaku jointly announced on February 3 that they have agreed to dissolve their agreement on joint development of NF-kappa B decoy oligodeoxynucleotide (NFkB decoy-oligo).

Twitter
LinkedIn
Facebook
Email
Print

Alliances Asia